Success for combination Zelboraf + cobimetinib in Advanced Melanoma - Genentech/Roche
Genentech, a member of the Roche Group announced positive data from the coBRIM Phase III study. The results showed that people with previously untreated BRAF V600 mutation-positive Advanced Melanoma who received the MEK inhibitor cobimetinib plus Zelboraf (vemurafenib) lived significantly longer without their disease worsening or death (progression-free survival; PFS) compared to Zelboraf alone.
The combined therapy reduced the risk of disease worsening or death by half (hazard ratio [HR]=0.51, 95 percent confidence interval [CI] 0.39-0.68; p<0.0001), with a median pfs of 9.9 months for cobimetinib plus zelboraf compared to 6.2 months with zelboraf alone. the safety profile was consistent with a previous study of the combination. the most common adverse events seen in the combination arm included diarrhea, nausea, rash, photosensitivity and lab abnormalities.>
The study was published online in the New England Journal of Medicine.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins